Market LIVE
Published markets; coverage varies by country
Product profile · United States

APTENSIO XR

 ·  Patent Litigation & Settlement History ↓

IngredientMETHYLPHENIDATE HYDROCHLORIDE
Application typeNDA
Application205831
Product001
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
Strength10MG
Approval date2015-04-17
Marketing statusPrescription
Status event—
ApplicantRHODES PHARMS
Product source

Current GenericRadar decision

Year2018
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2018-12-13
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2018-12-13
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
205831 / 001AUTHORIZED_GENERIC_REPORTED · AUTHORIZED_GENERIC_REPORTED——Rhodes Pharmaceuticals L.P.YEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
077707 / 001FINAL_APPROVAL · FINAL_APPROVED2012-07-19—TEVA PHARMACEUTICALS USANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
079031 / 004FINAL_APPROVAL · FINAL_APPROVED2014-10-15—BARR LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203583 / 001FINAL_APPROVAL · FINAL_APPROVED2015-09-29—SPECGX LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205105 / 001FINAL_APPROVAL · FINAL_APPROVED2016-07-28—IMPAX LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
200886 / 001FINAL_APPROVAL · FINAL_APPROVED2018-02-26—DR REDDYS LABORATORIES SANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208861 / 001FINAL_APPROVAL · FINAL_APPROVED2018-12-13—ACTAVIS ELIZABETH LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211796 / 001FINAL_APPROVAL · FINAL_APPROVED2019-05-23—GRANULES PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 1 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
205831 / 001Rhodes Pharmaceuticals L.P.AUTHORIZED_GENERIC_REPORTED · AUTHORIZED_GENERIC_REPORTED— EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 7 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
077707 / 001TEVA PHARMACEUTICALS USAFINAL_APPROVAL · FINAL_APPROVED2012-07-19 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
079031 / 004BARR LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED2014-10-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203583 / 001SPECGX LLCFINAL_APPROVAL · FINAL_APPROVED2015-09-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205105 / 001IMPAX LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED2016-07-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
200886 / 001DR REDDYS LABORATORIES SAFINAL_APPROVAL · FINAL_APPROVED2018-02-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208861 / 001ACTAVIS ELIZABETH LLCFINAL_APPROVAL · FINAL_APPROVED2018-12-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211796 / 001GRANULES PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2019-05-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2018-12-13TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.